key: cord-0796882-o5g2wclz
authors: Boushra, Marina N.; Koyfman, Alex; Long, Brit
title: COVID-19 in pregnancy and the puerperium: A review for emergency physicians
date: 2020-11-02
journal: Am J Emerg Med
DOI: 10.1016/j.ajem.2020.10.055
sha: 6dbd2b390f5008584560a0661bbf7c525b79bd4c
doc_id: 796882
cord_uid: o5g2wclz

BACKGROUND: Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) is a novel virus responsible for causing the novel coronavirus disease of 2019 (COVID-19). OBJECTIVE: This article discusses the clinical manifestations of COVID-19 in pregnant patients, the effects of pregnancy on the course of COVID-19 disease, and the impact of COVID-19 on pregnancy outcomes. DISCUSSION: The physiological and mechanical changes associated with pregnancy increase maternal susceptibility to infections and complicate intubation and mechanical ventilation. The most common symptoms of COVID-19 in pregnant patients are cough and fever, although many infected individuals are asymptomatic. The majority of pregnant women diagnosed with COVID-19 disease have a mild course of illness and will recover without needing to deliver, but the risk of critical illness and need for mechanical ventilation are increased compared to the general population. Risk factors for death and severe disease include obesity, diabetes, and maternal age > 40 years. Women in their third trimester have the highest risk for critical illness, intensive care unit admission, and need for mechanical ventilation. Adverse fetal outcomes of maternal COVID-19 infection include increased risk of miscarriage, prematurity, and fetal growth restriction. Vertical transmission of SARS-CoV-2 is possible but has not been conclusively proven. CONCLUSIONS: COVID-19 is a potentially deadly infection, but data are limited concerning the pregnant population. Pregnant patients appear to present similarly to the general population, with fever and cough being the most reported symptoms in studies. Knowledge of these presentations and outcomes can assist clinicians caring for these patients.

Data from SARS-CoV-1 and MERS-CoV can also inform the response to SARS-CoV-2 until more specific data are available. In examining the SARS-CoV-1 and MERS-CoV outbreaks, significant morbidity and mortality were most common among patients in the second and third trimesters of pregnancy. 5 Adverse outcomes included miscarriage, small for gestational age neonates, and prematurity. 5 Fever, cough, and fatigue were the most commonly reported symptoms with both SARS-CoV-1 and MERS-CoV. 6 The most common laboratory abnormalities were lymphocytopenia, elevated C-reactive protein (CRP), and leukopenia. 6 A meta-analysis of pregnant women hospitalized for infection with SARS-CoV-1, MERS-CoV, or SARS-CoV-2 noted that 90% of these patients demonstrated radiographic evidence of pneumonia either on plain x-ray or computed tomography (CT), even when asymptomatic. 6 This meta-analysis also noted an increased rate of preterm birth, caesarean delivery, neonatal intensive care unit (NICU) admission, and preeclampsia in women diagnosed with any of the three coronaviruses compared to the general population. 6 There have been no documented cases of vertical transmission of SARS-CoV-1 or MERS-CoV. 5, 6 

Testing in non-pregnant individuals most commonly occurs when they present with symptoms or a concerning contact history, whereas pregnant individuals are often tested for COVID-19 when presenting for care for pregnancy or reasons unrelated to the COVID-19 outbreak. 5, 6 A living systematic review of 28 studies including 11,432 patients found that 1 in 10 pregnant or recentlypregnant women presenting or admitted to the hospital tested positive for COVID-19. 7 Of these, three quarters were asymptomatic, and one in twenty asymptomatic pregnant women presenting J o u r n a l P r e -p r o o f or admitted to the hospital tested positive for Similar to the general population, the predominant features of symptomatic COVID-19 in pregnant patients were fever, cough, dyspnea, and lymphopenia. 7 The largest cohort study to date reported cough and fever as the most common symptoms in pregnant women presenting with COVID-19, 33% and 29%, respectively, rates similar to the 40% and 39% reported in the Allotey et al. cohort study. 7, 8 Compared to non-pregnant women of reproductive age, pregnant or recently-pregnant women with COVID-19 were less likely to report fever or myalgias. 7 A French cohort study suggested that the presence of gastrointestinal symptoms was associated with more severe disease. 9 Symptoms do not appear to differ based on gestational age at the time of presentation. 10 Both leukocytosis and leukopenia occur commonly in pregnant patients with COVID-19. A small case study noted that leukocytosis, lymphopenia, increased neutrophil ratio, and normal presenting temperature were more common in pregnant versus nonpregnant women with COVID-19. 10 In contrast, a later meta-analysis found leukopenia to be the most common laboratory abnormality in these patients (66.1%) but supported the finding of lymphopenia as a common abnormality (48.3%). 6 Other common laboratory abnormalities reported in the literature include an elevated C-reactive protein (CRP), D-dimer, and lactate dehydrogenase (LDH). 10, 11 The most common CT finding of COVID-19 pneumonia in pregnant patients included ground glass opacities and bilateral infiltrates. 6, 7, 10, 11 A meta-analysis of 42 studies comprising 247 pregnant patients with COVID-19 found that focal unilateral or bilateral ground-glass opacities were the most common imaging findings in mild or asymptomatic disease, while all patients with critical illness had diffuse bilateral ground-glass opacities with subpleural involvement and pleural effusion on imaging. 5, 6 This study found abnormal imaging in 89% of patients, 8.7% of J o u r n a l P r e -p r o o f whom were asymptomatic at the time of imaging. 11 This is similar to studies including patients with SARS-CoV-1 and MERS-CoV, which showed that abnormal imaging findings were common in asymptomatic pregnant patients. 5, 6 Given the prevalence of community spread of SARS-CoV-2 and relatively high rates of positive testing in otherwise asymptomatic individuals, it is important to not fall prey to premature closure in pregnant patients who test positive for COVID-19. 12 Many conditions common to pregnancy can present with fever, cough, or dyspnea, and COVID-19 increases risk for several common pregnancy conditions, including pre-eclampsia and pulmonary embolism (PE). 7 The differential diagnosis for the symptoms of COVID-19 in pregnancy is broad and includes PE, cardiomyopathy, pleural or pericardial effusion, pre-eclampsia, gestational rhinitis, physiologic dyspnea, and other etiologies of viral/bacterial pneumonia. Common complications of pregnancy and the puerperium should remain high on the differential for these patients, regardless of the results of COVID-19 testing. Patients should be evaluated for these common conditions based on their history and examination. Table 1 demonstrates the most common signs and symptoms, laboratory findings, and imaging findings in pregnant patients with COVID-19. Other studies also demonstrate severe outcomes in pregnant patients with COVID-19. While estimated mortality rates for pregnant patients with COVID-19 are 0.6-2%, comparable to the general population, those with critical disease at the time of presentation account for the vast majority of deaths secondary to COVID-19. 7,11 A recent study found an increased risk of severe illness and mechanical ventilation in pregnant women compared to their non-pregnant counterparts when adjusted for age, race, and co-morbidities. 19 The rate of intensive care admission rises with increasing gestational age, with one study reporting more than 90% of pregnant patients requiring ICU in their third trimester. 11 Data suggest 40% of pregnant patients who died from COVID-19 had obesity, diabetes, or maternal age greater than or equal to 40 years. 7, 11, 17, 19 Complications of severe illness include the need for invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO), preterm delivery, and COVID-J o u r n a l P r e -p r o o f related cardiomyopathy. 19 Pregnant women with COVID-19 were more likely to require mechanical ventilation and admission to an ICU. Increased maternal age, high body mass index, pre-existing hypertension, and pre-existing diabetes were associated with severe COVID-19, and the presence of maternal co-morbidities was a risk factor for ICU admission and mechanical ventilation. 7, 8, 10, 11 The severity of maternal disease correlated with risk for NICU admission or neonatal death. 11 The combination of elevated D-dimer and interleukin-6 levels was likewise associated with more severe disease and found to be present in 60% of severely ill and 80% of critically ill pregnant women with COVID-19, respectively. 11 

The PRIORITY study, which included 179 infants born to COVID-positive mothers and 84

infants born to COVID-negative mothers, found no increased risk of preterm birth, NICU J o u r n a l P r e -p r o o f admission, and respiratory disease in the COVID-positive cohort, although NICU admission and preterm birth were increased in the sub-group of mothers testing positive 0-14 days before delivery. 2, 4, [8] [9] [10] [11] [13] [14] [15] 18, [24] [25] [26] The largest cohort study to date followed the courses of 242 COVID-19 positive pregnant women and their 248 infants through the third trimester of pregnancy and one month postpartum. 11 Notable outcomes of this study include a higher rate of caesarean delivery and premature birth in patients hospitalized due to COVID-19 symptoms, findings that have been replicated in several cohort studies and meta-analyses. 11 It is uncertain whether the higher rate of prematurity derives from a need to deliver secondary to COVID-19 related maternal complications or from effects of the disease on the pregnancy. Rates of preterm birth and caesarean delivery are increased in COVID-19 patients regardless of the severity of disease,

suggesting that these outcomes may be iatrogenic. One meta-analysis found that preterm delivery occurred in approximately one third of patients with COVID-19. 11 Of these, 40% were early preterm deliveries (occurring between 24 weeks and 33 weeks 6 days gestation), and 60% were late preterm deliveries (occurring between 34 weeks and 36 weeks 6 days gestation). 11 Rates of caesarean delivery are extremely high in COVID-19 patients in this meta-analysis, with reported rates of nearly 85%. 25, 26 Notably, they also found that the only documented indication for caesarean delivery in approximately half of these cases was maternal COVID- 19, again suggesting that this effect may be iatrogenic in nature. 11 Data on fetal complications from COVID-19 are limited. Evidence suggests that miscarriage is more common in patients who became ill in the first trimester compared to the second trimester, with rates of 16.1% and 3.5%, respectively. [27] [28] [29] [30] While direct data are not available, abnormal fetal growth due to placental insufficiency is a concern in pregnant patients due to documented J o u r n a l P r e -p r o o f uteroplacental vascular malperfusion, intervillous inflammation, and thrombosis of fetal intervillous vessels in maternal COVID-19 infection. 8 This concern derives from 4 studies reporting on the histopathological examinations of 14 placentas from patients with clinically mild COVID-19 which found occlusive fibrin deposition and non-occlusive thrombi with placental hypoperfusion in all specimens. 11, 31 Half of these cases resulted in preterm delivery, and one case each of placental abruption, second-trimester miscarriage, and small for gestational age infant were also reported. [23] [24] [25] [26] Neonates whose mothers were admitted for the treatment of COVID-19 infection had an odds ratio of 3 of prematurity, regardless of the severity of maternal disease. 24 Spontaneous preterm labor is not increased compared to the general population, and caesarean sections account for nearly all the preterm deliveries reported. 7 Accordingly, most of the complications in neonates born to COVID-19 positive mothers are a result of prematurity rather than COVID-19 infection.

Infants with mothers who tested positive closer to delivery were more likely to be admitted to the NICU than those with mothers who tested positive two or more weeks prior to delivery. 8 Stillbirths and neonatal death rates are not increased compared to the general population. 8 In a recent cohort study, nearly a tenth of the neonates born to COVID-19 positive mothers presented to the ED in the first month of life. 24 None tested positive for COVID-19. [32] [33] [34] [35] This is in line with the findings of the PRIORITY study, which reported no cases of pneumonia or lower respiratory disease in neonates born to COVID-positive mothers at 6-8 weeks of age. 33, 35 Several case series report mild symptoms in neonates diagnosed with COVID-19 at or shortly after birth. [32] [33] [34] [35] The most common findings of COVID-19 in neonates are fever, pneumonia, cyanosis, respiratory distress, and feeding intolerance. 8 The majority of patients in these case series had mild J o u r n a l P r e -p r o o f symptoms and favorable outcomes, and most complications were related to prematurity and sepsis, rather than SARS-CoV-2. 11, 24 Vertical transmission of SARS-CoV-2 remains widely debated. No cases of vertical or horizontal transmission were found in the Marin Gabriel at al study. 8 have been found in seronegative neonates born to COVID-19 infected mothers. 26,27 This is notable because Ig-M antibodies cannot cross the placenta, suggesting a fetal immune response against the virus in neonates born to an infected mother. While SARS-CoV-2 has been isolated from maternal vaginal mucosa and stool samples, it has also been isolated from cord blood, placenta, and amniotic fluid, and there are no data to suggest that caesarean delivery is safer or reduces the risk of vertical transmission of SARS-CoV-2 in these patients. 11

Human data on the effects of COVID-19 treatments on pregnancy are limited. Current treatments for patients with COVID-19 include dexamethasone, convalescent plasma, and the antiviral medication remdesivir. 36 The RECOVERY trial, which demonstrated a mortality benefit of dexamethasone in patients with COVID-19 who required respiratory support, did include J o u r n a l P r e -p r o o f pregnant and breastfeeding patients and reported no pregnancy-associated adverse outcomes. 37 Use of high doses of dexamethasone in early pregnancy has been associated with poor pregnancy outcomes in mice, mares, and dogs. 38 These outcomes included early pregnancy termination, impaired fetal growth, and abnormal placentation. 38 However, the RECOVERY trial utilized dexamethasone 6 mg daily, which is not high dose. 37 54 Data on ECMO as a rescue therapy in pregnant patients with critical COVID-19 are limited, but it may be associated with favorable maternal and fetal outcomes in pregnant patients failing other therapies. 11, 55 Because the success of ECMO as a salvage therapy is often dependent on its early use, consultation and potential transfer to an ECMO expert center should be considered in patients with critical disease failing conventional therapy. 7, 11, 55 

Patients with mild disease and no co-morbidities can generally be discharged home with close return precautions, as approximately 3% will develop more severe disease (Figure 1 ). 11 Consideration should be given to hospitalizing patients with mild disease complicated by one or more comorbidities, as these patients have a higher risk of decompensation and severe disease. 16 Factors associated with more severe disease include obesity, hypertension, diabetes mellitus, maternal age greater than 40 years, and third-trimester pregnancy. 16 Those with severe or critical J o u r n a l P r e -p r o o f disease should be hospitalized, preferably at a center that has obstetrics services and an adult and neonatal ICU (Figure 1 ). 8 Figure 1 : Algorithm for the disposition of pregnant patients with COVID-19.

Patients diagnosed with COVID-19 in late pregnancy or the puerperium may express concern about breastfeeding. Evidence regarding the transmission of SARS-CoV-2 in breastmilk is limited and therefore insufficient to make a recommendation for or against breastfeeding by COVID-19 infected mothers. Two studies looking at a total of 9 patients found no molecular evidence of the virus in breastmilk, whereas one study reported finding the virus in breastmilk more than one week after delivery. 56,57 Given the paucity of evidence for transmission in breastmilk and the proven benefits of breastfeeding, the WHO and the Centers for Disease

Control and Prevention recommend continued breastfeeding by mothers who are COVID-19

positive as long as basic hygiene measures are followed, including the wearing of a facemask by the mother during feeding. 58,59 One study noted a decreased rate of breastfeeding in COVID-19 positive mothers, a factor previously documented to be associated with maternal-newborn separation at birth, which has been common in mothers positive for COVID-19. 8 

WHO Director-General's opening remarks at the media briefing on COVID-19 -11

Pulmonary Infections in Pregnancy. Seminars in Respiratory and Critical Care Medicine

Another decade, another coronavirus

Severe Coronavirus Infections in Pregnancy: A Systematic Review

The effect of coronavirus infection (SARS-CoV-2, MERS-CoV, and SARS-CoV) during pregnancy and the possibility of vertical maternalfetal transmission: a systematic review and meta-analysis

Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: Living systematic review and meta-analysis

P on behalf of the N-C-19 RG. Maternal, perinatal, and neonatal outcomes with COVID-19: a multicenter study of 242 pregnances and their 248 infant newborns during their first month of life

Covid-19 in pregnant women: General data from a French National Survey

Pregnancy and perinatal outcomes of women with coronavirus disease (COVID-19) Pneumonia: A preliminary analysis

Clinical characteristics, prognostic factors, and maternal and neonatal outcomes of SARS-CoV-2 infection among hospitalized pregnant women: A systematic review

Clinical characteristics of asymptomatic and symptomatic patients with mild COVID-19

Care of critically ill pregnant patients with coronavirus disease 2019: a case series

Coronavirus disease 2019 in pregnant women: a report based on 116 cases

Mode of Delivery and Clinical Findings in COVID

Infected Pregnant Women in Northern Italy

Managing COVID-19-Positive Maternal-Infant Dyads: An Italian Experience

Incidence and clinical profiles of COVID-19 pneumonia in pregnant women: A single-centre cohort study from Spain

An analysis of 38 pregnant women with COVID-19, their newborn infants, and maternal-fetal transmission of SARS-CoV-2: Maternal coronavirus infections and pregnancy outcomes

Characteristics of Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status -United States

COVID-19 and Cardiovascular Disease

COVID-19-related disease severity in pregnancy

Two cases of coronavirus 2019-related cardiomyopathy in pregnancy

Infant Outcomes Following Maternal Infection with SARS-CoV-2: First Report from the PRIORITY Study

How to reduce the potential risk of vertical transmission of SARS-CoV-2 during vaginal delivery?

Placental Pathology in Covid-19 Positive Mothers: Preliminary Findings. Pediatric and Developmental Pathology

Pregnant women with new coronavirus infection: a clinical characteristics and placental pathological analysis of three cases

Placental abruption in a twin pregnancy at 32 weeks' gestation complicated by coronavirus disease 2019 without vertical transmission to the babies

Second-Trimester Miscarriage in a Pregnant Woman with SARS-CoV-2 Infection

Characteristics and Outcomes of Pregnant Women Hospitalised with Confirmed SARS-CoV-2 Infection in the UK: A National Cohort Study Using the UK Obstetric Surveillance System (UKOSS) The UK Obstetric Surveillance System SARS-CoV-2 Infection in Pregnancy

Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. The Lancet

Novel Coronavirus Infection in Hospitalized Infants under 1 Year of Age in China

Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia

Neonatal Early-Onset Infection with SARS-CoV-2 in 33

Neonates Born to Mothers with COVID-19 in Wuhan

Therapeutic management of patients with COVID-19: a systematic review. Infection Prevention in Practice

Dexamethasone for COVID-19-Preliminary Report Effect of Dexamethasone in Hospitalized Patients with COVID-19-Preliminary Report RECOVERY Collaborative Group*. medRxiv

Steroids, Pregnancy and Fetal Development

Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients

COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2. -Full Text View -ClinicalTrials

A randomized, controlled trial of Ebola virus disease therapeutics

Use of remdesivir for pregnant patients with severe novel coronavirus disease 2019

Hydroxychloroquine early in Pregnancy and Risk of Birth Defects

Chloroquine and hydroxychloroquine during pregnancy: What do we know? Therapies

A Meta-Analysis on the Effects of Hydroxychloroquine on COVID-19

Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019

Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases

Ocular toxicity in children exposed in Utero to antimalarial drugs: Review of the literature

Coronavirus disease 2019 in pregnancy: consider thromboembolic disorders and thromboprophylaxis

Respiratory Failure and Mechanical Ventilation in the Pregnant Patient

Management of Acute Respiratory Failure in Pregnancy. Seminars in Respiratory and Critical Care Medicine

Mechanical Ventilation in Pregnancy Due to COVID-19: A Cohort of Three Cases

Successful Use of Extracorporeal Membrane Oxygenation Postpartum as Rescue Therapy in a Woman With COVID-19

Negative Transmission of SARS-CoV-2 to Hand-Expressed Colostrum from SARS-CoV-2-Positive Mothers

Breastfeeding and COVID-19: Scientific brief-2-Limitations